Wollin L - Search Results

1

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Wollin L, et al. Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Eur Respir J. 2015. PMID: 25745043 Free PMC article. Review.

2

Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo.

Wex E, Bouyssou T, Duechs MJ, Erb KJ, Gantner F, Sanderson MP, Schnapp A, Stierstorfer BE, Wollin L. Wex E, et al. Among authors: wollin l. Eur J Immunol. 2011 Nov;41(11):3208-18. doi: 10.1002/eji.201141502. Epub 2011 Sep 26. Eur J Immunol. 2011. PMID: 21830208 Free article.

3

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Wollin L, et al. J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi: 10.1124/jpet.113.208223. Epub 2014 Feb 20. J Pharmacol Exp Ther. 2014. PMID: 24556663

4

The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.

Wex E, Kollak I, Duechs MJ, Naline E, Wollin L, Devillier P. Wex E, et al. Among authors: wollin l. Br J Pharmacol. 2015 Jul;172(14):3537-47. doi: 10.1111/bph.13143. Epub 2015 May 12. Br J Pharmacol. 2015. PMID: 25824824 Free PMC article.

5

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.

Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, Distler JH. Huang J, et al. Among authors: wollin l. Ann Rheum Dis. 2016 May;75(5):883-90. doi: 10.1136/annrheumdis-2014-207109. Epub 2015 Apr 9. Ann Rheum Dis. 2016. PMID: 25858641

6

Interpretation of data from studies of effects of nintedanib on surfactant protein-D expression in human lung epithelial cells.

Wollin L. Wollin L. Pulm Pharmacol Ther. 2015 Aug;33:15-6. doi: 10.1016/j.pupt.2015.05.007. Epub 2015 May 29. Pulm Pharmacol Ther. 2015. PMID: 26027552 No abstract available.

7

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Bonella F, Stowasser S, Wollin L. Bonella F, et al. Among authors: wollin l. Drug Des Devel Ther. 2015 Dec 14;9:6407-19. doi: 10.2147/DDDT.S76648. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26715838 Free PMC article. Review.

8

Effects of nintedanib on the microvascular architecture in a lung fibrosis model.

Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ, Kreuz S, Stiller D, Wollin L, Konerding MA. Ackermann M, et al. Among authors: wollin l. Angiogenesis. 2017 Aug;20(3):359-372. doi: 10.1007/s10456-017-9543-z. Epub 2017 Mar 10. Angiogenesis. 2017. PMID: 28283856 Free PMC article.

9

Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator.

De Ruysscher D, Granton PV, Lieuwes NG, van Hoof S, Wollin L, Weynand B, Dingemans AM, Verhaegen F, Dubois L. De Ruysscher D, et al. Among authors: wollin l. Radiother Oncol. 2017 Sep;124(3):482-487. doi: 10.1016/j.radonc.2017.07.014. Epub 2017 Jul 31. Radiother Oncol. 2017. PMID: 28774597

10

Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.

Herrmann FE, Wollin L, Wirth J, Gantner F, Lämmle B, Wex E. Herrmann FE, et al. Among authors: wollin l. Br J Pharmacol. 2017 Nov;174(21):3848-3864. doi: 10.1111/bph.13982. Epub 2017 Sep 20. Br J Pharmacol. 2017. PMID: 28810065 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters